



Masters in Thoracic Oncology Summit

Lake Tahoe, Nevada | November 21-24, 2024

Thursday, November 21, 2024

08:00am	Registration Check-in
09:30am – 11:30am	Advisory Boards Groups A & B Elite Platinum only (up to 10 KOLs) First Come First Serve.
01:00pm – 03:00pm	Advisory Boards Groups C-D-E Elite Diamond only (up to 20 KOLs)
04:30pm – 06:30pm	Advisory Boards Groups F-G-H Elite Diamond only (up to 20 KOLs)
07:00pm – 9:00pm	VIP Reception with KOLs & Faculty Dinner <i>Elite Diamond Sponsors</i>

Friday, November 22, 2024

07:30am	Registration Check-in
08:00am – 08:15am	Welcome & Introductions Chairs: Marina Garassino, MD, Christine Lovly, MD, PhD, Luis E. Raez, MD, & Edgardo S. Santos, MD
Session I 08:15am – 09:30am	Lung Cancer Screening and Early Molecular Diagnosis Moderator: Luis E. Raez, MD
08:15am – 08:25am	Establishing a Lung Cancer Screening Program Karen Reckamp, MD
08:25am – 08:35am	How sensitive have to be a test to detect cancer and how about cancer interception and Methylation for Early Detection? Christian Rolfo, MD

08:35am – 08:45am	Development of Incidental Pulmonary Nodule Programs (IPNs) Gerard Silvestri, MD
08:45am – 08:55am	Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms Matthew Smeltzer, MD
08:55am – 09:30am	Q & A Session Moderator: Luis E. Raez, MD Misty Shields, MD, PhD Panel: Reckamp, Rolfo, Shields, Silvestri, Smeltzer
09:30am – 10:30am	Educational Plated Breakfasts (Non-CE) <i>Presented by Elite Diamond & Elite Platinum Sponsors (First Come First Serve)</i> Sponsored Program Room 1 Sponsored Program Room 2 Sponsored Program Room 3
10:30am – 10:45am	Coffee Break Visit Industry Connections
Session II 10:45am – 11:45am	Early-Stage Resectable Lung Cancer Moderator: Mark Socinski, MD
10:45am – 10:55am	What is the Best Way to Assess Complete Pathologic Response ? Lynnette Scholl, MD
10:55am – 11:05am	Perioperative Chemo/Immunotherapy and Surgical Outcomes. Jay M. Lee, MD
11:05am – 11:25am	Debate: Is Perioperative Immunotherapy the New Standard of Care?
11:05am - 11:15am	Yes: Tina Cascone, MD
11:15am – 11:25am	No: Hossein Borghaei, DO
11:25am – 11:35am	How Can We Characterize Those Patients Who Need Adjuvant Treatment? David Gandara, MD
11:35am – 11:45am	Q & A Session Moderator: Mark Socinski

Panel: Borghaei, Bradley, Cascone, Gandara, Lee, Reckamp, Scholl,

Session III
11:45am – 12:50pm

11:45am – 12:00pm
12:00pm – 12:15pm
12:15pm – 12:30pm
12:30pm – 12:45pm
12:45pm – 12:50pm

Early-Stage NSCLC-Case-Based Panel Discussion
Moderator: Karen Kelly, MD

5 min Presentation | 10 min Panel Discussion

Case #1. Mary Jo Fidler, MD

Case #2. Erminia Massarelli, MD

Case #3. Hatim Husain, MD

Case #4. Jason Porter, MD

Wrap-up Session

Panel: Carbone, Fidler, Husain, Massarelli, Porter, Vokes

Session IV
12:50pm – 01:15pm

01:15pm- 01:20pm

Keynote Presentation

Update Progress in Targeted Therapies for Early Stage NSCLC discussing Neoadjuvant and Adjuvant options.

Lyudmila Bhazenova, MD

Moderator: Luis E. Raez, MD

Questions and Answers

01:20pm – 02:20pm

Educational Lunches (Non-CE)

Elite Diamond & Platinum Sponsors

Sponsored Program | Room 1

Sponsored Program | Room 2

Sponsored Program | Room 3

02:20pm – 02:35pm

Break | Visit Industry Connections

Session V
02:35pm – 03:35pm

02:35pm – 02:45pm

Locally Advanced NSCLC-Unresectable (Stage III)

Moderator: Daniel Morgensztern, MD

Assessing Resectability in Stage III NSCLC

Jessica Donington, MD

02:45pm – 02:55pm

Combining immunotherapy with radiation for LANSCLC.

Megan Daly, MD

02:55pm – 03:05pm

Moving the Bar Beyond PACIFIC. What is the best consolidation therapy for people with actionable and non-actionable genes?

Balaz Halmos, MD

03:05pm- 03:35pm

Q & A Session

Moderator: Daniel Morgenstern, MD | Rajat Thawani, MBBS

Panel: Donignton, Daly, Halmos, Iyengar, Langer, Thawani

Session VI

03:35pm – 04:40pm

Locally Advanced NSCLC-Unresectable; Case-Based Panel Discussion

Moderator: Corey Langer, MD

03:35pm – 03:45pm

Case #1. Localized Advanced NSCLC w Driver Mutation
Raja Mudad, MD

03:45pm – 03:55pm

Case #2. Localized Advanced NSCLC w/o Driver Mutation
Misty Shields, MD

03:55pm – 04:05pm

Case #3. Localized Advanced NSCLC w PDL-1 No Expression
Wade Iams, MD

04:05pm – 04:15pm

Case #4. Localized Advanced NSCLC w Driver Mut (no EGFR/no ALK)
Kim Chul, MD

04:15pm – 04:40pm

Wrap-up Session

Moderator: Corey Langer, MD

Panel: Bradley, Chul, Iams, Massarelli, Mudad, Shields, Simon, Spigel

04:40pm – 04:45pm

Meeting Adjourns | Day 1

Luis E. Raez, MD

04:50pm – 06:50pm

Advisory Boards **Groups I-J-K-L** | Elite Platinum
(up to 10 KOLs)

07:00pm – 09:00pm

VIP Reception with KOLs & Faculty Dinner

Elite Diamond Sponsors

Saturday, November 23, 2024

7:30am

Registration | Check-in

08:00am – 08:05am

Welcome & Introductions

Moderators:

Marina Garassino, MD and Christine Lovly, MD, PhD

Session VII**08:05am – 09:20am****Small Cell Lung Cancer (SCLC)****Moderator: Paul Bunn, MD**

08:05am – 08:15am

Advances in Biomarkers for SCLC
Lauren Byers, MD

08:15am – 08:25am

SCLC: Where Are We At?
Catherine Meador, MD

08:25am – 08:35am

SCLC: Where Are We Going?
Charles Rudin, MD

08:35am – 08:45am

Role of Radiation Therapy in SCLC
Puneeth Iyengar, MD

09:05am – 09:20am

Q & A Session**Moderator:** Paul Bunn, MD | Noura Choudry, MD**Panel:** Byers, Choudry, Hirsch, Iyengar, Meador, Rudin**09:20am – 10:20am****Educational Plated Breakfasts (Non-CE)***Presented by Diamond & Platinum Sponsors*

Sponsored Program | Room 1

Sponsored Program | Room 2

Sponsored Program | Room 3

10:20am – 10:35am

Break | Visit Industry Connections

Session VIII**10:35am – 11:40am****Metastatic NSCLC with Genomic Alterations-
Case-Based Panel Discussion****Moderator: Christine Lovly, MD, PHD**

10:35am – 10:45am

Case #1. EGFR First Line Therapy
Xiuning Le, MD

10:45am – 10:55am

Case #2. Progression after Third Generation EGFR TKI or
Other Therapies
Jonathan Riess, MD

10:55am – 11:05am

Case #3. ALK First Line
Julia Rotow, MD

11:05am – 11:15am

Case #4. Progressing on ALK TKI and Acquired
Resistance on ALK Domain
Ibiagy Dagogo-Jack, MD

- 11:15am – 11:25am Case #5. Progressing on ALK TKI with Acquired Resistance in an Alternative Pathway
Erminia Massarelli, MD
- 11:25am – 11:35am Case #6. K-Ras other than G12C after First Line Therapy
Kim Chul, MD
- 11:35am – 11:40am Wrap-up Session
Moderator: Christine Lovly, MD, PhD
Panel: Chul, Dagogo-Jack, Heymach, Hirsch, Le, Massarelli, Ou, Riess, Rotow

Session IX

11:40am – 12:45pm

Metastatic NSCLC with Genomic Alterations- Case-Based Panel Discussion

Moderator: Edgardo Santos, MD

- 11:40am – 11:50am Case #1. ROS1 First Line or At Progression
Justin Gainor, MD
- 11:50am -12:00pm Case #2. RET First Line or a Progression Case
Alexander Drilon, MD
- 12:00pm – 12:10pm Case #3. MET First Line or a Progression Case
Deborah Doroshaw, MD
- 12:10pm – 12:20pm Case #4. Her2 Mutation First Line or a Progression Case
Stephen Liu, MD
- 12:20pm – 12:30pm Case #5. B-RAF No V600E First Line or At Progression
Millie Das, MD
- 12:30pm – 12:40pm Case #6. NTRK First Line
Mary Jo Fidler, MD
- 12:40pm – 12:45pm Wrap-up Session
Moderator: Edgardo Santos, MD
Panel: Aggarwal, Baik, Doroshaw, Drilon, Fidler, Gainor, Liu, Salgia

Session X

12:45pm – 01:10pm
Specifics

Keynote Presentation

The Era of Antibody-Drug Conjugates (ADCs) and Bi-

Speaker: Jyoti Patel, MD

01:10pm – 01:15 pm

Moderator: Marina Garassino, MD

Question and Answers

01:15pm – 02:15pm

Educational Lunches (Non-CE)

Presented by Diamond & Platinum Sponsors

Sponsored Program | Room 1

Sponsored Program | Room 2

Sponsored Program | Room 3

Session XI

02:20pm – 03:20pm

Drug Development Forum | Pipeline Presentations in Lung Cancer (Non-CE)

Moderator: Edgardo Santos, MD

10 min each | Presented by Elite Diamond Sponsors

Diamond Sponsor A

Diamond Sponsor B

Diamond Sponsor C

Diamond Sponsor D

Diamond Sponsor E

Diamond Sponsor F

03:20pm – 03:30pm

Break | Visit Industry Connections

Session XII

03:30pm – 04:35pm

Metastatic NSCLC with Genomic Alterations

Moderator: Cristina Baik, MD

03:30pm – 03:40pm

Developing of Resistance to KRAS Inhibitors
Matthew Gubens, MD

03:40pm – 03:50pm

STK11, KEAP and TP53 as Co-Mutations with Bad
Prognosis is there a Predictive Role?
Ferdinando Skoulidis, MD

03:50pm – 04:00pm

Exon 20 insertions what will be the ideal therapy?
Zosia Piotrowska, MD

04:00pm – 04:10pm

BRAF and NTRK inhibitors in NSCLC
Julie Brahmer, MD

04:10pm - 04:35pm

Moderator: Cristina Baik, MD

Panel: Brahmer, Gubbens, Piotrowska, Skoulidis

Session XIII

04:35pm – 05:55pm

**Metastatic NSCLC without Genomic Alterations-
Case-Based Panel Discussion**

Moderator: Marina Garassino, MD

04:35pm – 04:45pm

Case #1. Never Smoker without An Actionable Mutation
Tejas Patil, MD

04:45pm – 04:55pm	Case #2. Second Line Therapy after Immunotherapy or Chemo/Immunotherapy in Squamous Cell Carcinoma Deborah Doroshaw, MD
04:55pm – 05:05pm	Case #3. First Line Immunotherapy with STK11 or KEAP1 mutations and PDL-1 >50% Adenocarcinoma Biagio Ricciuti, MD
05:05pm – 05:15pm	Case #4. First Line Immunotherapy with with STK11 or KEAP1 mutations and PDL-1 0% Adenocarcinoma Nagla Karim, MD
05:15pm – 05:25pm	Case #5. First Line Immunotherapy with Squamous histology and PDL-1 0% Jorge Gomez, MD
05:25pm – 05:35pm	Case #6. First Line with Squamous histology and asymptomatic (1-2 subcentimeter lesions) in the brain, and PDL-1 35% (1-49%) Sonam Puri, MD
05:35pm – 05:45pm	Case #7. Second-line After chemo/Immunotherapy and on Maintenance IO Joshua Reuss, MD
05:45pm – 05:55pm	Wrap-up Session Moderator: Marina Garassino, MD Panel: Cascone, Doroshaw, Gadgeel, Gomez, Karim, Patil, Puri, Reuss, Ricciuti, Simon, Spiegel
05:55pm – 06:00pm	Meeting Adjourns Day 2 Christine Lovly, MD, PhD
06:00pm – 7:30pm	Sundowner Reception with KOLs <i>Elite Platinum & Gold Sponsors</i>
08:00pm – 10:00pm	Faculty Dinner

Sunday, November 24, 2024

07:00am – 09:00am	Farewell “Grab and Go” Breakfast for KOLs Location: Lobby Area
07:00am – 09:00am	Post-Conference Advisory Boards or SWOTs